Welcome to our dedicated page for Definium Therapeutics SEC filings (Ticker: DFTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Definium Therapeutics, Inc. (DFTX) SEC filings page on Stock Titan is designed to help readers review the company’s regulatory disclosures in one place. While no specific filings are listed in the provided data, Definium references documents such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q in its public communications, indicating that it files reports with the U.S. Securities and Exchange Commission.
Stock Titan connects to the SEC’s EDGAR system so that when Definium Therapeutics submits new filings, they can be displayed with AI-generated summaries. These summaries are intended to highlight key themes in lengthy documents, such as risk factor discussions, updates on the company’s psychiatric and neurological drug pipeline, and commentary on clinical study progress for candidates like DT120 ODT and DT402 as described in the company’s public statements.
For investors and researchers, this page can provide access to core filing types, including annual reports on Form 10-K and quarterly reports on Form 10-Q, once available. It can also surface other filing categories that may be relevant over time, such as registration statements or current reports, which often discuss material events, clinical milestones, or capital-raising activities referenced in the company’s forward-looking disclosures.
In addition to listing documents as they are filed, Stock Titan’s AI tools can help explain complex regulatory language in more accessible terms. This can be useful when reviewing sections that discuss Definium Therapeutics’ focus on psychedelic-inspired psychiatry, its clinical trial programs in generalized anxiety disorder, major depressive disorder, and autism spectrum disorder, and the risks and uncertainties the company highlights in its own cautionary statements.
Definium Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on novel psychedelic-derived treatments for brain health disorders. Its lead candidate, DT120 ODT (lysergide D-tartrate), is in Phase 3 programs for generalized anxiety disorder (GAD) and major depressive disorder (MDD), following a Phase 2b GAD trial that met primary and key secondary endpoints and received FDA breakthrough therapy designation and a UK ILAP Innovation Passport.
The GAD Phase 3 program includes the Voyage and Panorama trials, while MDD trials include Emerge and Ascend, each with randomized, double-blind, placebo-controlled Part A phases and 40‑week open‑label extensions. A second candidate, DT402 (R(-)-MDMA), is in a Phase 2a trial for autism spectrum disorder. The company reports no approved products, ongoing net losses, the need for substantial additional capital, reliance on third-party manufacturers and CROs, and regulatory and reimbursement risks, particularly given its use of controlled substances.
Definium Therapeutics reported a larger full-year 2025 net loss of
Cash, cash equivalents and investments rose to
Research and development expenses increased to
Definium highlighted progress across four Phase 3 trials of DT120 ODT in major depressive disorder and generalized anxiety disorder, with its Emerge MDD study fully enrolled and multiple topline readouts anticipated in
Definium Therapeutics, Inc.7.2% of the company as of December 31, 2025. This position includes 2,000,000 common shares plus 5,428,775 shares that can be acquired through a pre-funded warrant, which is subject to a 9.99% beneficial ownership limitation. The ownership percentage is based on 98,509,279 common shares reported outstanding as of October 31, 2025, plus the warrant shares. The filing is made jointly by Commodore Capital LP, Commodore Capital Master LP, and managing partners Robert Egen Atkinson and Michael Kramarz, who certify that the securities are not held for the purpose of changing or influencing control of the issuer. The issuer recently changed its name from Mind Medicine (MindMed) Inc. to Definium Therapeutics, Inc.
Driehaus Capital Management LLC, a Delaware investment adviser, reported beneficial ownership of Definium Therapeutics, Inc. common stock. Driehaus has shared voting and dispositive power over 6,537,202 shares, representing 6.64% of the company’s common stock as of the event date.
The shares are held in numerous fully discretionary client accounts managed by Driehaus, which reports potential voting and dispositive power, while clients generally do not hold more than 5% of the class individually. Driehaus states the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Definium Therapeutics.
Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a new significant ownership position in Definium Therapeutics, Inc. They beneficially own 5,000,000 Common Shares, representing 5.08% of the class, with sole voting and dispositive power over these shares.
The ownership percentage is based on 98,509,279 Common Shares outstanding as of October 31, 2025, as referenced from the company’s Form 10-Q for the quarter ended September 30, 2025. The investors state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Definium Therapeutics, Inc. received an amended Schedule 13G from Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin reporting a significant ownership position. The group reports beneficial ownership of 5,676,540 common shares, representing 5.54% of the class as of December 31, 2025.
This total includes 4,000,000 pre-funded warrants exercisable into common shares, calculated against 102,509,279 shares (98,509,279 shares outstanding as of October 31, 2025 plus the warrant shares). The warrants are subject to a 9.99% Maximum Percentage cap on post-exercise ownership, limiting how many can be exercised at any time.
The reporting persons state that the securities were not acquired to change or influence control, indicating a passive investment intent under the relevant SEC rules.
Definium Therapeutics, Inc. granted its Chief Commercial Officer, Matthew T. Wiley, 115,000 common shares in the form of restricted stock units (RSUs). The grant was reported as an acquisition at a price of $0.00 per share, held directly by the officer.
Each RSU represents a contingent right to receive one common share of Definium Therapeutics. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, as long as Wiley continues providing service to the company on each vesting date.
Definium Therapeutics, Inc. granted its Chief Financial Officer, Brandi Roberts, an award of 150,000 restricted stock units (RSUs). Each RSU represents the right to receive one common share.
The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, as long as Roberts continues providing service on each vesting date. The award was reported as a direct, no-cost acquisition, with 150,000 common shares beneficially owned following the transaction.
Definium Therapeutics, Inc. Chief Legal Officer Mark Sullivan reported an equity award of 125,000 common shares in the form of restricted stock units on February 3, 2026. The award was granted at a price of $0.00 per share as part of his compensation.
Each RSU represents a right to receive one common share, vesting in 16 equal quarterly installments beginning June 1, 2026, so long as he continues providing service on each vesting date. Following this grant, he beneficially owns 407,576 common shares directly.
Definium Therapeutics, Inc. Chief Medical Officer Dan Karlin reported an award of 150,000 common shares of the company on February 3, 2026. These are structured as restricted stock units, granted at a price of $0.00 per share, increasing his direct holdings to 575,025 shares.
The RSUs vest in 16 equal quarterly installments starting on June 1, 2026. Each RSU converts into one common share if he continues providing service to Definium Therapeutics on each vesting date, tying the value of this grant to his ongoing tenure.